Protective effects of atypical antipsychotic drugs against MPP+-induced oxidative stress in PC12 cells

Neuroscience Research

Volumn 69, Issue 4, 2011, Pages 283-290

  Park, Sung Woo ^a   Lee, Chan Hong ^a   Lee, Jung Goo ^a,b   Kim, Luck Woo ^a   Shin, Bae Sub ^a   Lee, Bong Ju ^a,b   Kim, Young Hoon ^a,b  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Atypical antipsychotic drug; Bax; MPP+; Oxidative stress; ROS; SOD

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ZIPRASIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPSYCHOTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BENZODIAZEPINES; BLOTTING, WESTERN; CELL SURVIVAL; HALOPERIDOL; HERBICIDES; OXIDATIVE STRESS; PC12 CELLS; PIPERAZINES; QUINOLONES; RATS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; THIAZOLES;

EID: 79951958579     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2011.01.004     Document Type: Article

References (60)

1. Al-Chalabi B.M., Thanoon I.A., Ahmed F.A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 2009, 59:8-11.
2. Andreasen N.C. Positive and negative symptoms of schizophrenia. Acta Psychiatr. Scand. 1994, 90:51-59.
3. Bai O., Wei Z., Lu W., Bowen R., Keegan D., Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 2002, 69:278-283.
4. Behl C., Rupprecht R., Skutella T., Holsboer F. Haloperidol-induced cell death mechanism and protection with vitamin E in vitro. Neuroreport 1995, 7:360-364.
5. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochem. Biophys. Acta 1999, 1453:49-62.
6. Crompton M. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr. Opin. Cell Biol. 2000, 12:414-419.
7. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
8. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
9. Dipasquale B., Marini A.M., Youle R.J. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem. Biophys. Res. Commun. 1991, 181:1442-1448.
10. Eren I., Naziroĝlu M., Demirdaş A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res. 2007, 32:1188-1195.
11. +-induced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 1999, 55:620-628.
12. Fenton W.S., Hibbeln J., Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry 2000, 47:8-21.
13. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 2007, 420:45-48.
14. +) and 4-phenylpyridineanalogs in inner membrane preparation. J. Biol. Chem. 1994, 269:3167-3174.
15. Greenlund L.J., Deckwerth T.L., Johnson E.M. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995, 14:303-315.
16. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr. Bull. 2010, 36:472-485.
17. Herken H., Uz E., Ozyurt H., Söĝüt S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 2001, 6:66-73.
18. Jarskog L.F., Selinger E.S., Lieberman J.A., Gilmore J.H. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry 2004, 161:109-115.
19. Ji Y., Pang P.T., Feng L., Lu B. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat. Neurosci. 2005, 8:164-172.
20. Kirkland R.A., Windelborn J.A., Kasprzak J.M., Franklin J.L. A Bax-induced prooxidant state is critical for cytochrome c release during programmed neuronal death. J. Neurosci. 2002, 22:6480-6490.
21. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 2002, 20:171-175.
22. Kurosawa S., Hashimoto E., Ukai W., Toki S., Saito S., Saito T. Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J. Neural Transm. 2007, 114:1121-1128.
23. +-induced mitochondrial damage and cell death by trifluoperazine and W-7 in PC12 cells. Neurochem. Int. 2005, 46:169-178.
24. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1001-1006.
25. Lessmann V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 2003, 69:341-374.
26. Lieberman J.A., Perkins D.O., Jarskog L.F. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr. 2007, 12:1-13.
27. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 1990, 28:535-539.
28. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol. Bull. 1995, 31:159-165.
29. Lotharius J., Dugan L.L., O'Malley K.L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 1999, 19:1284-1293.
30. Lud Cadet J., Harrington B., Ordonez S. Bcl-2 overexpression attenuates dopamine-induced apoptosis in an immortalized neural cell line by suppressing the production of reactive oxygen species. Synapse 2000, 35:228-233.
31. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996, 19:1-8.
32. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry 1998, 43:674-679.
33. Matsuo T., Izumi Y., Kume T., Takada-Takatori Y., Sawada H., Akaike A. Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures. Neurosci. Lett. 2010, 481:78-81.
34. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J. Neurochem. 1995, 65:1740-1751.
35. McCreadie R.G., MacDonald E., Wiles D., Campbell G., Paterson J.R. The Nithsdale Schizophrenia Surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br. J. Psychiatry 1995, 167:610-617.
36. Meltzer H.Y. Atypical antipsychotic drugs. Psychopharmacology: The Fourth Generation of Progress 1995, Raven Press, New York, pp. 1277-1286.
37. Mochizuki H., Nakamura N., Nishi K., Mizuno Y. Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat. Neurosci. Lett. 1994, 170:191-194.
38. Mukerjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996, 19:19-26.
39. Mutoh T., Tokuda A., Marini A.M., Fujiki N. 1-methyl-4-phenylpyridinium kills differentiated PC12 cells with a concomitant change in protein phosphorylation. Brain Res. 1994, 661:51-55.
40. Naidu P.S., Singh A., Kulkarni S.K. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Psychopharmacology (Berl) 2003, 167:418-423.
41. Noh J.S., Kang H.J., Kim E.Y., Sohn S., Chung Y.K., Kim S.U., et al. Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. J. Neurochem. 2000, 75:2327-2334.
42. Parikh V., Khan M.M., White J.R. Atypical antipsychotics such as risperidone and clozapine do not induce the oxidative stress and the lipid peroxidation similar to haloperidol in rats. Biol. Psychiatry 2002, 51:184-185.
43. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003, 37:43-51.
44. Park S.W., Lee C.H., Lee J.G., Lee S.J., Kim N.R., Choi S.M., et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. J. Psychiatr. Res. 2009, 43:274-281.
45. Park S.W., Lee J.G., Ha E.K., Choi S.M., Cho H.Y., Seo M.K., Kim Y.H. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur. Neuropsychopharmacol. 2009, 19:356-362.
46. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 1993, 13:4246-4253.
47. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007, 41:372-386.
48. +-induced apoptosis. Eur. J. Neurosci. 2003, 17:1563-1570.
49. Smythies J.R. Oxidative reactions and schizophrenia: a review-discussion. Schizophr. Res. 1997, 24:357-364.
50. Singh O.P., Chakraborty I., Dasgupta A., Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J. Psychiatry 2008, 50:171-176.
51. Schubert D., Klier F.G. Storage and release of acetylcholine by a clonal cell line. Proc. Natl. Acad. Sci. USA 1977, 74:5184-5188.
52. Stadtman E.R. Role of oxidant species in aging. Curr. Med. Chem. 2004, 11:1105-1112.
53. Tipton K.F., Singer T.P. Advances in our understanding of the mechanism of the cytotoxicity of MPTP and related compounds. J. Neurochem. 1993, 61:1191-1206.
54. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998, 32:385-391.
55. Wakada C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002, 69:72-79.
56. Wang H., Xu H., Dyck L.E., Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide (25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 2005, 81:572-580.
57. Wei Z., Bai O., Richardson J.S., Mousseau D.D., Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 2003, 73:364-368.
58. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid (25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J. Neurosci. Res. 2003, 74:942-947.
59. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81:291-300.
60. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., et al. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry 2007, 68:754-760.